23.19 USD
+0.17 (+0.74%)
Overall QURE gets a fundamental rating of 3 out of 10. We evaluated QURE against 525 industry peers in the Biotechnology industry. QURE has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, QURE is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year QURE has reported negative net income.
- QURE had a negative operating cash flow in the past year.
- QURE had negative earnings in 4 of the past 5 years.
- QURE had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- QURE's Return On Assets of -26.47% is fine compared to the rest of the industry. QURE outperforms 69.71% of its industry peers.
- Looking at the Return On Equity, with a value of -102.80%, QURE is in line with its industry, outperforming 45.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.47% | ||
| ROE | -102.8% | ||
| ROIC | N/A |
ROA(3y)-32.71%
ROA(5y)-18.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- QURE's Gross Margin of 88.13% is amongst the best of the industry. QURE outperforms 90.29% of its industry peers.
- In the last couple of years the Gross Margin of QURE has declined.
- The Profit Margin and Operating Margin are not available for QURE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.13% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.17%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- QURE does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for QURE has been increased compared to 1 year ago.
- Compared to 5 years ago, QURE has more shares outstanding
- QURE has a worse debt/assets ratio than last year.
2.2 Solvency
- QURE has an Altman-Z score of -0.55. This is a bad value and indicates that QURE is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of QURE (-0.55) is comparable to the rest of the industry.
- QURE has a Debt/Equity ratio of 2.26. This is a high value indicating a heavy dependency on external financing.
- QURE has a worse Debt to Equity ratio (2.26) than 79.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.26 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.55 |
ROIC/WACCN/A
WACC6.38%
2.3 Liquidity
- QURE has a Current Ratio of 7.12. This indicates that QURE is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of QURE (7.12) is better than 70.29% of its industry peers.
- A Quick Ratio of 7.12 indicates that QURE has no problem at all paying its short term obligations.
- QURE has a Quick ratio of 7.12. This is in the better half of the industry: QURE outperforms 70.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.12 | ||
| Quick Ratio | 7.12 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 11.11% over the past year.
- The Revenue for QURE has decreased by -44.90% in the past year. This is quite bad
- The Revenue has been growing by 30.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-51.65%
Revenue 1Y (TTM)-44.9%
Revenue growth 3Y-62.73%
Revenue growth 5Y30.01%
Sales Q2Q%61.83%
3.2 Future
- QURE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.19% yearly.
- Based on estimates for the next years, QURE will show a very strong growth in Revenue. The Revenue will grow by 72.19% on average per year.
EPS Next Y19.6%
EPS Next 2Y15.49%
EPS Next 3Y14.73%
EPS Next 5Y21.19%
Revenue Next Year-60.9%
Revenue Next 2Y-2.54%
Revenue Next 3Y63.14%
Revenue Next 5Y72.19%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for QURE. In the last year negative earnings were reported.
- Also next year QURE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as QURE's earnings are expected to grow with 14.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.49%
EPS Next 3Y14.73%
5. Dividend
5.1 Amount
- QURE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
UNIQURE NV / QURE FAQ
Can you provide the ChartMill fundamental rating for UNIQURE NV?
ChartMill assigns a fundamental rating of 3 / 10 to QURE.
What is the valuation status for QURE stock?
ChartMill assigns a valuation rating of 0 / 10 to UNIQURE NV (QURE). This can be considered as Overvalued.
What is the profitability of QURE stock?
UNIQURE NV (QURE) has a profitability rating of 2 / 10.
How financially healthy is UNIQURE NV?
The financial health rating of UNIQURE NV (QURE) is 3 / 10.
What is the expected EPS growth for UNIQURE NV (QURE) stock?
The Earnings per Share (EPS) of UNIQURE NV (QURE) is expected to grow by 19.6% in the next year.